Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Alexandre de Muralt to Lead Merck Serono Japan
September 29, 2017
- Novartis Japan Chief Sees CAR-T Pricing as “Important Issue” Here Too
September 29, 2017
- VLP Flu Vaccine Enters PIII in North America, Europe: Mitsubishi Tanabe
September 28, 2017
- Sumitomo Dainippon to Slash Manufacturing Jobs via Another Voluntary Redundancy Program
September 28, 2017
- Nichi-Iko Earns Remicade Biosimilar Nod, Picks GI-Savvy Zeria as Copromotion Ally
September 28, 2017
- Japan Approves 1st Rituxan Biosimilar from Sandoz
September 28, 2017
- Fujifilm Takes 6% Stake in Japanese Regenerative Medicine Upstart
September 27, 2017
- FDA Accepts sNDA for Lenvima’s HCC Indication
September 27, 2017
- Medipal’s JCR Deal Aimed at Adding Value to Its Distribution Biz in Japan?
September 27, 2017
- Konica Minolta to Acquire Boston CRO Invicro
September 26, 2017
- Mitsubishi Tanabe Seeks to Block Talion Generic Launches by 3 Makers
September 26, 2017
- Hisamitsu Launches US PII Study for Analgesic Transdermal Patch
September 26, 2017
- Shionogi Initiates Rolling NDA Submission in US for Lusutrombopag
September 26, 2017
- Daiichi Sankyo’s Esaxerenone Hits Primary Endpoint in Patients with Essential Hypertension
September 26, 2017
- Medipal/JCR Want to Establish JV by Year End, Go Global with 8 Products
September 25, 2017
- Pfizer to Discontinue 5 Generics, Transition Period Slated until March 2019
September 25, 2017
- Opdivo Gains Nod for Gastric Cancer; Spinraza Now Available for All SMA Patients
September 25, 2017
- Asahi Kasei Obtains Japan Development Rights for Autologous Cell Therapy Product from Belgium Company
September 25, 2017
- Teva’s Parkinson’s Med Delivers Positive Data in Japan PIII: Takeda
September 22, 2017
- Medipal to Become JCR’s Top Shareholder, Poised to Form JV in US
September 22, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…